Metabolic Changes in Blood Samples From Patients With Acute Myeloid Leukemia

Wake Forest University (WFU)

Status: Completed

Conditions: Untreated Adult Acute Myeloid Leukemia; Recurrent Adult Acute Myeloid Leukemia

Treatments: Other: Cytology Specimen Collection Procedure; Other: Laboratory Biomarker Analysis

Study type: Observational

Funder types: Other; NIH

Identifiers

NCT02581917

P30CA012197 (U.S. NIH Grant/Contract)

CCCWFU 22A15 (Other Identifier)

NCI-2015-01267 (Registry Identifier)

IRB00034202

Details and patient eligibility

About

This research trial studies metabolic changes in blood samples from patients with acute myeloid leukemia. Studying samples of blood from patients with acute myeloid leukemia in the laboratory may help doctors learn more about cancer and the development of drug resistance.

Full description

PRIMARY OBJECTIVES:

I. To determine the metabolic adaptations that occur following exposure to standard chemotherapeutic agents using peripheral blood mononuclear cells from acute myeloid leukemia (AML) patients.

OUTLINE:

Patients undergo collection of peripheral blood mononuclear cell (PBMC) samples for analysis via cell isolation, glycolytic flux and oxygen consumption assays, viability assays, and western blot at baseline, 24, 48, and 72 hours after starting chemotherapy.

Enrollment: 14 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients scheduled to initiate chemotherapy for either an initial diagnosis of AML or relapsed AML
• Starting the initial induction phase of therapy
• Exposure to hydroxyurea is acceptable but must be noted at the time of sample collection
• Ability to understand and the willingness to sign an institutional review board (IRB)-approved informed consent

Exclusion criteria

• Received at least one dose of chemotherapy during the current cycle (excluding hydroxyurea).

Trial design

14 participants in 1 patient group

Ancillary-Correlative (metabolic changes)

Description:

Patients undergo collection of PBMC samples for analysis via cell isolation, glycolytic flux and oxygen consumption assays, viability assays, and western blot at baseline, 24, 48, and 72 hours after starting chemotherapy.

Treatment:

Other: Laboratory Biomarker Analysis

Other: Cytology Specimen Collection Procedure